GDTC logo

CYTOMED THERAPEUTICS LTD

GDTCNASDAQ
🏆 #4962 by market capUS Equity
$0.91▼ $0.06 (−6.08%)
After hours · at close
🔔
Track GDTC
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 6.1%
7d▲ 0.0%
14d▲ 12.8%
30d▼ 5.2%
ytd▼ 33.1%
1y▼ 53.1%
🏦Market Cap
$11M
Small Cap
📈Revenue Growth (YoY)
+359.3%
High Growth
📊Gross Margin
-20.5%
Thin
💵FCF Margin
-986.0%
Thin
⚖️P/S Ratio
22.5x
Expensive
Otter Score
76
Good

Trading Snapshot

Day Range
$0.90 – $0.92
52-Week Range
$0.68 – $3.68
Volume
$2.23B
Avg Volume
$1.89B
Shares Outstanding
11.8M
Next Earnings
Nov 6, 2026

Fundamentals Snapshot

Annual Revenue
$319,201
Last Q Revenue
$167,945
P/E Ratio
-3.0
P/S Ratio
22.5x
EPS (TTM)
$-0.41
Dividend Yield
0.00%
Dilution (1yr)
+2.2%

Why Investors Own GDTC

  • ✓High-growth profile — revenue up +47.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 50% gross margin and 24% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

GDTC logo

CYTOMED THERAPEUTICS LTD

GDTC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$319K▲ +359.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-277.7%▼ −468.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$5M▲ +44.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$4M▲ +7.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
11.8M▲ +2.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▼ −$3M YoY
StockOtter · stockotter.space

About CYTOMED THERAPEUTICS LTD

CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Price Target

ⓘ
Average Target
$1.19
▲ +31.3% Upside
High Target$1.47
Low Target$1.04
Based on 30 analysts

Latest News & Updates

🚀
Barron’s·2h ago

CYTOMED THERAPEUTICS LTD tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift GDTC price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

CYTOMED THERAPEUTICS LTD announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.